CN114555624A - 抗炎剂 - Google Patents

抗炎剂 Download PDF

Info

Publication number
CN114555624A
CN114555624A CN202080052404.9A CN202080052404A CN114555624A CN 114555624 A CN114555624 A CN 114555624A CN 202080052404 A CN202080052404 A CN 202080052404A CN 114555624 A CN114555624 A CN 114555624A
Authority
CN
China
Prior art keywords
thr
pro
ser
ala
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080052404.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·佩恩
S·N·伯恩
D·M·麦克唐纳
A·S·阿什赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901968A external-priority patent/AU2019901968A0/en
Application filed by University of Sydney filed Critical University of Sydney
Publication of CN114555624A publication Critical patent/CN114555624A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202080052404.9A 2019-06-06 2020-06-05 抗炎剂 Pending CN114555624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901968 2019-06-06
AU2019901968A AU2019901968A0 (en) 2019-06-06 Anti-inflammatory agents
PCT/AU2020/050572 WO2020243787A1 (en) 2019-06-06 2020-06-05 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
CN114555624A true CN114555624A (zh) 2022-05-27

Family

ID=73652576

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052404.9A Pending CN114555624A (zh) 2019-06-06 2020-06-05 抗炎剂

Country Status (6)

Country Link
US (1) US20230002446A1 (enExample)
EP (1) EP3980440A4 (enExample)
JP (3) JP2022536289A (enExample)
CN (1) CN114555624A (enExample)
AU (2) AU2020289132A1 (enExample)
WO (1) WO2020243787A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409759B (zh) * 2022-01-28 2022-07-12 长春普思康医疗科技有限公司 一种具有抑菌功能的rp23蛋白
CN118453838B (zh) * 2024-07-12 2024-10-01 昆明医科大学第一附属医院(云南省皮肤病医院) 倭蛙皮肤抗氧化肽antioxidin-NV在制备皮肤抗炎、抗过敏的药物中的应用
CN119219737B (zh) * 2024-11-15 2025-09-16 华南农业大学 一种贝壳珍珠层来源抗炎活性肽及其在制备皮肤修复产品中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028505A2 (en) * 2003-09-25 2005-03-31 Hadasit Medical Research Services And Development Ltd. Multiepitope polypeptides for cancer immunotherapy
WO2008035350A1 (en) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008111996A2 (en) * 2006-07-20 2008-09-18 Dana-Farber Cancer Institute, Inc. Muc1-ikb kinase complexes and their activities
WO2010006177A2 (en) * 2008-07-10 2010-01-14 Dana-Farber Cancer Institute, Inc. Muc1, caspase-8,and ded-containing proteins
WO2010138740A1 (en) * 2009-05-27 2010-12-02 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of muc1
US20120045502A1 (en) * 2010-02-12 2012-02-23 Kufe Donald W Antagonists of muc1
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298522B1 (en) * 2005-05-13 2012-10-30 Kwang Chul Kim Methods of modulating MUC1 expression to inhibit inflammation
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028505A2 (en) * 2003-09-25 2005-03-31 Hadasit Medical Research Services And Development Ltd. Multiepitope polypeptides for cancer immunotherapy
WO2008111996A2 (en) * 2006-07-20 2008-09-18 Dana-Farber Cancer Institute, Inc. Muc1-ikb kinase complexes and their activities
WO2008035350A1 (en) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2010006177A2 (en) * 2008-07-10 2010-01-14 Dana-Farber Cancer Institute, Inc. Muc1, caspase-8,and ded-containing proteins
WO2010138740A1 (en) * 2009-05-27 2010-12-02 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of muc1
CN102665748A (zh) * 2009-05-27 2012-09-12 达娜-法勃肿瘤研究所公司 使用muc1拮抗剂抑制炎症
US20120045502A1 (en) * 2010-02-12 2012-02-23 Kufe Donald W Antagonists of muc1
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴梧桐主编: "《酶类药物学》", 31 January 2011, 中国医药科技出版社, pages: 82 - 83 *

Also Published As

Publication number Publication date
AU2020289132A1 (en) 2022-01-06
JP2022536289A (ja) 2022-08-15
WO2020243787A1 (en) 2020-12-10
AU2023233094A1 (en) 2023-10-05
AU2023233094B2 (en) 2025-09-18
JP2023126760A (ja) 2023-09-12
EP3980440A1 (en) 2022-04-13
EP3980440A4 (en) 2023-07-05
US20230002446A1 (en) 2023-01-05
JP2025122021A (ja) 2025-08-20

Similar Documents

Publication Publication Date Title
US11931412B2 (en) JAK1 inhibitors and uses thereof
JP6813613B2 (ja) アネキシン−１（リポコルチン１）をモジュレートすることによる自己免疫疾患の処置方法
CN106062000B (zh) 通过施用il-4r拮抗剂治疗皮肤感染的方法
AU2023233094B2 (en) Anti-inflammatory agents
JP5918750B2 (ja) Ｔｒｅｍ様転写物１（ｔｌｔ−１）から誘導された阻害性ペプチドおよびその使用
JP6165727B2 (ja) 新規ｉｌ−１７ｒ−ｅｃｄ変異体
JP6778681B2 (ja) Ｈｍｇｂ１媒介性炎症の治療
KR20120105429A (ko) 염증 치료 방법
JPWO2016093326A1 (ja) 血管新生病の免疫療法
US20170000851A1 (en) Ptd-smad7 therapeutics
US11472862B2 (en) IL13Rα2 peptide and its uses
KR20190034546A (ko) TATκ-CDKL5 융합 단백질, 그의 조성물, 제형 및 용도
WO2009103312A1 (en) Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
CA3178840A1 (en) Method of treating an inflammatory disorder
JP6987749B2 (ja) Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
JP2012512183A (ja) 改変された孔形成性タンパク質プロアエロリシンを用いた前立腺炎の処置のための方法
CN110139659B (zh) 用于治疗干燥综合征的肽
WO2021097146A1 (en) Methods and compositions for treating cancer
JP2007538017A (ja) 胃腸疾患の治療のためのｐｐｙ含有組成物
AU2018202086B2 (en) Yersinia outer protein m (yopm) in the treatment of psoriasis
WO2022032592A1 (en) Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination